Stay updated with breaking news from Stat Facts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 22, 2023--
Media Release TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to...
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK® (tisotumab vedoti...
Company AnnouncementPhase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for presentation at a future medical meetingGenmab and Seagen to engage in discussions with regulatory authoritiesCOPENHAG...